This cautionary tale does highlight the potential for OPMD but shows what investors think when results are mediocre. The $1B could be almost all ours if we get things right as the competition is virtually non-existent. However, we still have some way to go before we can expect to see OPMD research drive up the share price.
Add to My Watchlist
What is My Watchlist?
